Objective To explore the diagnostic value of dehydroepiandrosterone sulfate (DHEAS) combined with basal adrenocorticotropic hormone (ACTH) and cortisol testing in adrenal insufficiency (AI). Methods A retrospective study was conducted, enrolling 68 patients with AI (including 25 with primary adrenal insufficiency[PAI]and 43 with secondary adrenal insufficiency[SAI]) admitted to the Department of Endocrinology, Shantou Central Hospital, from July 2017 to July 2022, along with 99 healthy controls during the same period. Data on basal cortisol, ACTH, and DHEAS levels were collected for all three groups. Statistical methods were used to compare differences in these indicators among the groups. Receiver operating characteristic (ROC) curves were employed to evaluate the diagnostic value of single indicators (DHEAS, ACTH, basal cortisol) and their combination for AI, with a focus on the advantages of the combined approach in addressing the limitations of single indicators and reducing missed diagnosis rates. Results Among the 68 AI patients, the PAI group consisted of 25 cases (11 males, 14 females; mean age 46.85±12.89 years), the SAI group included 43 cases (17 males, 26 females; mean age 49.83±19.69 years), and the control group comprised 99 cases (38 males, 61 females; mean age 46.83±19.69 years). Compared with the control group (152.8±48.6 μg/dL), DHEAS levels were significantly lower in the SAI group (26.48±12.37 μg/dL) and even lower in the PAI group (14.8±9.68 μg/dL), with significant differences between any two groups. ACTH levels in the PAI group (359.8±142.6 pg/mL) were significantly higher than those in the control group (14.8±4.36 pg/mL), while no significant difference was observed between the SAI group (12.6±5.26 pg/mL) and the control group. ROC curve analysis revealed that the area under the curve (AUC) for DHEAS, ACTH, and basal cortisol alone in diagnosing AI was 0.710, 0.606, and 0.751, respectively, whereas the combined diagnosis of the three indicators significantly increased the AUC to 0.859. Conclusion The combined detection of DHEAS, ACTH, and basal cortisol enhances the diagnostic accuracy for adrenal insufficiency (AI), particularly in distinguishing between primary adrenal insufficiency (PAI) and secondary adrenal insufficiency (SAI). This approach is recommended for clinical application.
Key words
adrenocortical function /
adrenal insufficiency /
dehydroepiandrosterone sulfate /
basal cortisol /
adrenocorticotropic hormone
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] NEARY N, NIEMAN L.Adrenal insufficiency: etiology, diagnosis and treatment[J]. Curr Opin Endocrinol Diabetes and Obes, 2010, 17(3): 217-223.
[2] 杨小婷, 胡菊萍. 原发性肾上腺皮质功能减退症1例并文献复习[J]. 中国现代医生, 2024, 62(17): 125-127.
[3] HUSEBYE ES, PEARCE SH, KRONE NP, et al.Adrenal insufficiency[J]. Lancet, 2021, 397(10274): 613-629.
[4] MARTIN C R, PREEDY V R, RAJENDRAM R.Assessments, Treatments and Modeling in Aging and Neurological Disease[M]. Amsterdam: Academic Press, 2021.
[5] 邱平, 臧丽, 张丽, 等. 不同剂量促肾上腺皮质激素兴奋试验在原发性醛固酮增多症分型诊断中的比较[J]. 四川大学学报 (医学版), 2024, 55(1): 210-216.
[6] 张正, 田亚平, 周裕军, 等. 荧光免疫层析技术定量检测唾液、汗液皮质醇的建立和性能评价[J]. 标记免疫分析与临床, 2024, 31(12): 2322-2326.
[7] EBBEHOJ A, LI D, KAUR RJ, et al.Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study[J]. Lancet Diabetes Endocrinol, 2020, 8(11): 894-902.
[8] LIU MS, LOU Y, CHEN H, et al.Performance of DHEAS as a screening test for autonomous cortisol secretion in adrenal incidentalomas: a prospective study[J]. J Clin Endocrinol Metab, 2022, 107(5): e1789-e1796.
[9] 刘亚峰, 司英奎, 陈雪, 等. 原发性肾上腺皮质功能减退的研究进展[J]. 中国中医药现代远程教育, 2011, 9(24): 124-127.
[10] GRUBER LM, BANCOS I.Secondary adrenal insufficiency: recent updates and new directions for diagnosis and management[J]. Endocr Pract, 2022, 28(1): 110-117.
[11] FLESERIU M, AUCHUS R, BANCOS I, et al.Consensus on diagnosis and management of Cushing's disease: a guideline update[J]. Lancet Diabetes Endocrinol, 2021, 9(12): 847-875.
[12] 中华医学会内分泌学分会. 肾上腺皮质功能减退症诊疗指南 (2023年更新版)[J]. 中华内分泌代谢杂志, 2023, 39(4): 289-301.
[13] 付子仪, 谢婷婷. 信迪利单抗致免疫相关肾上腺皮质功能减退1例[J]. 中国药物应用与监测, 2022, 19(1): 66-68.
[14] 姜榴茗, 张晓妍, 刘新宇, 等. 原发性肾上腺皮质功能减退症临床特点分析[J]. 江苏医药, 2022, 48(3): 279-283.
[15] 杜维冠, 王海宁, 孙建军, 等. 成人肾上腺皮质功能减退症病因构成及临床特点单中心10年回顾[J]. 中国微创外科杂志, 2022, 22(8): 633-639.
[16] 李佳, 陈炯镇, 朱凯旋. 老年垂体大腺瘤合并医源性库欣综合征、继发性肾上腺皮质功能减退症1例报告与反思[J]. 解放军医学院学报, 2020, 41(8): 841-844.
[17] 徐忠森. 以新生儿低血糖首诊的先天性肾上腺皮质增生合并脂肪酸代谢障碍1例[J]. 中国乡村医药, 2021, 28(24): 46-47.
[18] 王龙, 卢琳, 陆召麟, 等. 原发性肾上腺皮质功能减退症的病因构成及临床特点[J]. 中华医学杂志, 2020, 100(12): 915-921.
[19] KVAM HELLAN K, LYNGSTAD M, METHLIE P, et al.Utility of salivary cortisol and cortisone in the diagnostics of adrenal insufficiency[J]. J Clin Endocrinol Metab, 2025, 110(5): 1218-1223.
[20] 房春云, 常丽纳, 何庆, 等. 原发性肾上腺皮质功能减退症临床分析[J]. 天津医科大学学报, 2021, 27(4): 401-404.
[21] 田朝阳, 刘梦思, 李梦莲, 等. 肾上腺性库欣综合征患者中枢性甲状腺功能减退的发生与术后下丘脑-垂体-肾上腺轴恢复时项的相关性研究[J]. 临床内科杂志, 2024, 41(5): 321-325.
[22] 张文婧, 李洪运, 张雪斌. 肾上腺源性雄激素在肾上腺静脉采血选择性判定中的作用[J]. 中华医学杂志, 2019, 99(12): 923-928.
[23] LAUGESEN K, BROERSEN LHA, HANSEN SB, et al.MANAGEMENT OF ENDOCRINE DISEASE: glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?[J]. Eur J Endocrinol, 2021, 184(4): R111-R122.
[24] HAN AJ, SURESH M, GRUBER LM, et al.Performance of dehydroepiandrosterone sulfate and baseline cortisol in assessing adrenal insufficiency[J]. J Clin Endocrinol Metab, 2025, 110(9): e3117-e3124.
[25] 潘萍, 李予. 不孕症合并肾上腺疾病的诊治[J]. 中国实用妇科与产科杂志, 2024, 40(6): 614-618.
[26] 郭钰英, 戴芳芳, 刘乾文, 等. 糖皮质激素预处理对PCOS患者辅助生殖助孕结局的影响[J]. 生殖医学杂志, 2024, 33(11): 1423-1429.
[27] 赵智瑞, 何国丽, 林琳, 等. PCOS患者和肽素、Ghrelin、DHEAS水平及与胰岛素抵抗的相关性研究[J]. 生殖医学杂志, 2022, 31(10): 1067-1072.
[28] 崔佳锦, 金玉珍. 多囊卵巢综合征患者血清DHEAS、TEST、sOB-R水平及临床意义[J]. 浙江医学, 2022, 44(4): 187-190, 193.